Factors Associated With Survival in Patients Having Pneumocystis Jirovecii

Recruiting

• Conditions: Pneumocystis Jirovecii Infection

• Registration Number: NCT06173453
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Pneumocystis jirovecii is a fungus that can colonize the airways of some patients and be responsible for a disease called pneumocystosis in other patients and mainly in immunocompromised patients.

Pneumocystosis was mainly linked to HIV in the 1990s, but with the advent of new immunosuppressive molecules used in cancers or autoimmune diseases and with the increase in the number of transplants, the epidemiology has changed in recent years.

Studies on P. jirovecii-related mortality are only based on patients with pneumocystosis. As a result, patients who are simply colonized or patients who are sick but not treated are not taken into account in these studies. The investigators therefore wish to study the overall mortality at six weeks and at three months in all patients with a positive sample for P. jirovecii

Detailed Description

Not available

Study Timeline

• Study Start: 2023-01-01
• Status Verified: 2023-06
• Study First Submitted: 2023-06-15
• Study First Submitted QC: 2023-12-13
• Last Update Submitted: 2023-12-13
• Study First Posted: 2023-12-15
• Last Update Posted: 2023-12-15
• Primary Completion: 2025-08-10
• Study Completion: 2025-10-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Survival at six weeks and three months after infection	six weeks after infection

Trial Locations

Locations (1)

Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France